<?xml version='1.0' encoding='utf-8'?>
<document id="16321557"><sentence text="[Insertion problems, removal problems, and contraception failures with Implanon]." /><sentence text="Analysis of the results of a national pharmacovigilance study on Implanon, a contraceptive implant containing 68 mg of etonogestrel"><entity charOffset="119-131" id="DDI-PubMed.16321557.s2.e0" text="etonogestrel" /></sentence><sentence text="" /><sentence text="This survey concerns cases of pregnancies (contraception failures), of migrations and of insertion or removal problems with Implanon reported to French Regional Drug Pharmacovigilance Centres and to Organon SA between May 2001 and September 2002" /><sentence text="" /><sentence text="In France, 39 unintended pregnancies were reported over 17 months" /><sentence text=" The pregnancies were in 77% of cases (N = 30) due to an insertion technique error (implant not found when pregnancy has been diagnosed)"><entity charOffset="39-40" id="DDI-PubMed.16321557.s7.e0" text="N" /></sentence><sentence text=" For 3 patients (7,6%), pregnancy was due to a failure of etonogestrel contraceptive effect, explained twice by its association with an enzymatic inductor drug"><entity charOffset="58-70" id="DDI-PubMed.16321557.s8.e0" text="etonogestrel" /></sentence><sentence text=" For 4 patients (10%), pregnancy was due to an untimely insertion (insertion after day 5 of menstrual cycle or woman already pregnant)" /><sentence text=" For two patients, no information was available" /><sentence text=" The incidence of reported pregnancies in France is estimated at 0" /><sentence text="359 / 10(3) implants [0" /><sentence text="246-0" /><sentence text="482], in accordance with a typical Pearl Index of 0" /><sentence text="06 [0" /><sentence text="04-0" /><sentence text="08]" /><sentence text=" Twenty-eight suspected migrations (N = 11), problems or failures in removal of the implant (N = 11) and insertion difficulties (N = 6) were notified, corresponding to an incidence of 0"><entity charOffset="36-37" id="DDI-PubMed.16321557.s18.e0" text="N" /><entity charOffset="93-93" id="DDI-PubMed.16321557.s18.e1" text="N" /><entity charOffset="129-129" id="DDI-PubMed.16321557.s18.e2" text="N" /><pair ddi="false" e1="DDI-PubMed.16321557.s18.e0" e2="DDI-PubMed.16321557.s18.e0" /><pair ddi="false" e1="DDI-PubMed.16321557.s18.e0" e2="DDI-PubMed.16321557.s18.e1" /><pair ddi="false" e1="DDI-PubMed.16321557.s18.e0" e2="DDI-PubMed.16321557.s18.e2" /><pair ddi="false" e1="DDI-PubMed.16321557.s18.e1" e2="DDI-PubMed.16321557.s18.e1" /><pair ddi="false" e1="DDI-PubMed.16321557.s18.e1" e2="DDI-PubMed.16321557.s18.e2" /></sentence><sentence text="257/10(3) implants [0" /><sentence text="162-0" /><sentence text="363]" /><sentence text="" /><sentence text="Occurrence of pregnancy is possible with Implanon, due to errors in the insertion technique (device not really inserted) or to a non-respect of the SPC recommendations (drug-drug interaction or untimely insertion)" /><sentence text=" Insertion problems can lead to localisation problems (implant not visible by X-ray) then needing further tests and even harmful practice (removal under general anaesthesia)" /><sentence text=" That is why a real and strict training is highly recommended to physicians" /><sentence text="" /></document>